Skip to main content
Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) Mazieres, J., Tomasini, P., Lusque, A., Boucekine, M., Gautschi, O., Cortot, A. B., Couraud, S., Thai, A., Ng, T., Greillier, L., Veillon, R., Neal, J. W., Popat, S., Gounant, V., Mhanna, L., Drilon, A., Baron, J., Barlesi, F. ELSEVIER. 2020: S826–S827

View details for DOI 10.1016/j.annonc.2020.08.1593

View details for Web of Science ID 000573469101565